research:comparison_of_combination_treatment_in_hypertension
Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision Next revision | Previous revision | ||
|
research:comparison_of_combination_treatment_in_hypertension [2017/04/16 13:19] burculantonija |
research:comparison_of_combination_treatment_in_hypertension [2017/08/07 08:42] (current) scyou [Discussion] |
||
|---|---|---|---|
| Line 3: | Line 3: | ||
| <WRAP box justify round> | <WRAP box justify round> | ||
| - | **Objective:** //The goal of this protocols is conducting comparative effectiveness research to establish evidences for optimal anti-hypertensive combination strategies among patients without cardiovascular outcome from various databases across world.// | + | **Objective:** The goal of this protocols is conducting comparative effectiveness research to establish evidences for optimal anti-hypertensive combination strategies among patients without cardiovascular outcome from various databases across world. |
| - | **Rationale:** //High blood pressure is the leading global burden of death and disability1. Extensive evidences support the beneficial effects in tight control of blood pressure. Since monotherapy is often insufficient or slow to reach blood pressure target quickly, combination therapy is recommended as the first-line treatment for selected patients with hypertension by the recent guideline to reduce cardiovascular risk. Retrospective observational studies and meta-analysis have suggested that initial combination hypertensive treatment confers decreased risk for cardiovascular events than monotherapy. Only a few randomized clinical trials, however, have directly compared the effects of different regimens of combination. In addition to limited number of evidences from head-to-head comparison, baseline high risk for cardiovascular outcome and previous history of anti-hypertensive medication of participants also make the findings from RCTs difficult to apply to clinical practice. To the best of our knowledge, real-world comparative effectiveness research comparing the various regimens of combination treatment in patients with essential hypertension has not been conducted until now. | + | **Rationale:** High blood pressure is the leading global burden of death and disability. Extensive evidences support the beneficial effects in tight control of blood pressure. Since monotherapy is often insufficient or slow to reach blood pressure target quickly, combination therapy is recommended as the first-line treatment for selected patients with hypertension by the recent guideline to reduce cardiovascular risk. Retrospective observational studies and meta-analysis have suggested that initial combination hypertensive treatment confers decreased risk for cardiovascular events than monotherapy. Only a few randomized clinical trials, however, have directly compared the effects of different regimens of combination. In addition to limited number of evidences from head-to-head comparison, baseline high risk for cardiovascular outcome and previous history of anti-hypertensive medication of participants also make the findings from RCTs difficult to apply to clinical practice. To the best of our knowledge, real-world comparative effectiveness research comparing the various regimens of combination treatment in patients with essential hypertension has not been conducted until now. |
| - | // | + | |
| - | **Project Lead(s):** //Seng Chan You, MD, Ajou University, Korea | + | |
| + | **Project Lead(s):** | ||
| + | Seng Chan You, MD, Ajou University, Korea | ||
| Sungjae Jung, BE, Ajou University, Korea | Sungjae Jung, BE, Ajou University, Korea | ||
| Sungha Park, MD, Yonsei university College of Medicine, Korea | Sungha Park, MD, Yonsei university College of Medicine, Korea | ||
| Rae Woong Park, MD, PhD, Ajou University, Korea | Rae Woong Park, MD, PhD, Ajou University, Korea | ||
| - | // | ||
| - | **Coordinating Institution(s):** //Ajou University, Korea// | + | **Coordinating Institution(s):** Ajou University, Korea |
| ** Additional Participants:** // | ** Additional Participants:** // | ||
| // | // | ||
| - | **Full Protocol:** //[[https://github.com/OHDSI/StudyProtocolSandbox/raw/master/HypertensionCombination/documents/HTN_combi_protocol_ver0.3(17.1.2).docx|Word doc for the protocol]] // | + | **Full Protocol:** [[https://github.com/OHDSI/StudyProtocolSandbox/blob/master/HypertensionCombination/documents/HTN_combi_protocol_ver1.1.docx|Word doc for the protocol]] |
| **Initial Proposal Date:** Sep 2016 | **Initial Proposal Date:** Sep 2016 | ||
| - | **Launch Date:** 16 Jan 2017 // // | + | **Launch Date:** 7 Aug 2017 |
| **Study Closure Date: // //** | **Study Closure Date: // //** | ||
| - | **Results Submission:** //<method of sumission, [[mailto:applegna@gmail.com|Email]]>// | + | **Results Submission:** Via Google Drive |
| </WRAP> | </WRAP> | ||
| ===== Requirements ===== | ===== Requirements ===== | ||
| - | **CDM:** //V5 only// | + | **CDM:** V5 or over |
| - | **Table Accessed:** //person, drug_exposure, drug_era, death, condition_occurrence, measurement, procedure_occurrence, visit_occurrence// | + | **Table Accessed:** person, drug_exposure, drug_era, death, condition_occurrence, procedure_occurrence, visit_occurrence |
| **Database Dialects:** SQL Server, Postgres, Oracle | **Database Dialects:** SQL Server, Postgres, Oracle | ||
| - | **Software:** //R// | + | **Software:** R |
| ===== Code ===== | ===== Code ===== | ||
| Line 44: | Line 44: | ||
| ===== Discussion ===== | ===== Discussion ===== | ||
| - | //Post a thread letting everyone know about this new proposed study at [[http://forums.ohdsi.org/c/researchers]]// | + | //[[http://forums.ohdsi.org/c/researchers]]// |
| ===== Datasets Run ===== | ===== Datasets Run ===== | ||
research/comparison_of_combination_treatment_in_hypertension.1492348789.txt.gz · Last modified: 2017/04/16 13:19 by burculantonija
Page Tools
